Navigation Links
Lilly Announces Retirement of Robert Armitage, Names Michael Harrington Senior Vice President and General Counsel
Date:8/30/2012

INDIANAPOLIS, Aug. 30, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Michael J. Harrington will be promoted to senior vice president and general counsel effective Jan. 1, 2013.  Harrington will replace Robert A. Armitage who will retire at the end of the year.

Harrington, vice president and deputy general counsel, is currently responsible for the legal function across Lilly's five business units.  In his new role, he will report to John Lechleiter, Ph.D., chairman, president, and CEO, and will serve on the company's executive committee.

Commenting on Armitage's career, Lechleiter stated, "Bob Armitage has left a lasting impact on Lilly and the biopharmaceutical industry with his exceptional contributions, particularly in the field of intellectual property. He also has provided keen insight and extraordinary leadership across a range of business issues affecting our company. It's been an absolute privilege to work with him."

Armitage played a major role in the successful efforts leading to the passage last year of the America Invents Act, which made the most sweeping changes to U.S. patent law in 175 years. In 2011, he became one of a select group of only 47 individuals who have been inducted in the Intellectual Property Hall of Fame, which includes U.S. presidents Jefferson and Madison. Armitage joined Lilly in 1999 as vice president and general patent counsel, Lilly Research Laboratories.  For the last decade, he has led Lilly's global legal organization as the company's general counsel.

Harrington is a graduate of the Columbia University School of Law. He joined the company in 1991 and has served in a number of business and legal positions with Lilly, including managing director of Eli Lilly New Zealand, general counsel for Lilly's Asia-Pacific operations and deputy general counsel with responsibility for all litigation, manufacturing, environmental and human resources matters.

"We are very fortunate to have Mike Harrington to take Bob's place. Mike is well-prepared for his new assignment. He has been instrumental in handling many of the key legal challenges we have faced in the last few years. His extensive global experience, deep knowledge of the business, and his passion for Lilly's mission will serve our company well," said Lechleiter.

About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information ─ for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.  C-LLY

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)

(Photo: http://photos.prnewswire.com/prnh/20120830/DE64980-a)

(Photo: http://photos.prnewswire.com/prnh/20120830/DE64980-b)

 


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lilly Stops Phase III Development of Pomaglumetad Methionil For the Treatment of Schizophrenia Based on Efficacy Results
2. U.S. Court of Appeals Upholds Validity of Lillys Alimta Compound Patent
3. Lilly Revises 2012 Reported Guidance to Reflect Income from Early Payment of Amylin Obligations
4. Lilly Announces Study Results Regarding Postmenopausal Women with Back Pain Caused by Vertebral Fractures
5. Lilly Supports Research to Determine What a Dogs Nose Knows About People with Diabetes and Severe Hypoglycemia
6. Lilly Reports Second-Quarter 2012 Results, Raises 2012 EPS Guidance
7. Lilly Confirms Date and Conference Call for Second-Quarter 2012 Financial Results Announcement
8. Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint of Clinical Study
9. Lilly Diabetes Announces Once Upon A Time Contest Winner
10. Lilly Statement on Affordable Care Act Ruling by Supreme Court
11. Lilly Statement on PDUFA Vote by Senate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... CLEVELAND , Jan. 18, 2017  ViewRay, ... the world,s first and only clinical MRI-guided radiation ... gross proceeds of approximately $26.1 million through a ... Puissance Capital Management led the financing and was ... OrbiMed Advisors, LLC and Kearny Venture Partners, and ...
(Date:1/19/2017)... 18, 2017 The Academy of Managed ... Administration (FDA) for its release today of draft ... decision makers can proactively share clinical and economic ... as emerging therapies awaiting FDA approval. ... that AMCP developed during two multi-stakeholder meetings last ...
(Date:1/18/2017)... 2017 Research and Markets has announced the addition ... User - Global Opportunity Analysis and Industry Forecast, 2014-2022" report to ... Vital signs ... to reach $5,491 million by 2022, growing at a CAGR of 5.8% ... was the leading regional market in global vital signs monitoring devices ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... 2017 , ... Students interested in video can get a jump start on ... earn a $1,000 scholarship and have his or her video posted on the GenCure ... May 31, with the winner announced on June 9. , The competition is designed ...
(Date:1/19/2017)... PA (PRWEB) , ... January 19, 2017 , ... Allegheny ... experience of patients who seek access to the Network’s programs and services in the ... primary or specialty care appointments will be offered one for that same afternoon. ...
(Date:1/19/2017)... ... January 19, 2017 , ... For ... serves Lawrenceville, New Jersey and the surrounding area, is inaugurating a charity ... (ALS), more commonly known as Lou Gehrig's disease or motor neurone disease, is ...
(Date:1/19/2017)... ... 2017 , ... For the second consecutive year, all five ... have earned “Top Doctor” awards. Dr. Mark Leondires, Dr. Spencer Richlin, Dr. Joshua ... by their peers for the 2017 list based on their exceptional patient care ...
(Date:1/19/2017)... ... , ... The 21st Century Cures Act’s Impact on Medical Devices:, What You ... 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/21stcenturycures          , What do ... this year? , The passage of the act means devicemakers will be scrambling to ...
Breaking Medicine News(10 mins):